AR101 Oral Immunotherapy for Peanut Allergy

Pediatrics - United States
doi 10.1542/peds.2019-2461uu
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Academy of Pediatrics (AAP)

Related search

Peanut Allergy and Oral Immunotherapy

Hong Kong Medical Journal
Medicine
2019English

Longer-Term Safety and Efficacy Measures of AR101 Oral Immunotherapy for Peanut Allergy: Results From a Phase 3 Follow-On Study

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Long Term Follow-Up of Oral and Sublingual Immunotherapy for Peanut Allergy

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Mannosylated Nanoparticles for Oral Immunotherapy in a Murine Model of Peanut Allergy

Journal of Pharmaceutical Sciences
Pharmaceutical Science
2019English

Impact of Peanut Allergy on Quality of Life: Baseline Results From PALISADE, a Phase 3, Double-Blind, Placebo-Controlled Trial for AR101 Oral Immunotherapy

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial

Pediatrics
Child HealthPediatricsPerinatology
2018English

Oral Immunotherapy for Food Allergy

Journal of Investigational Allergology and Clinical Immunology
AllergyImmunology
2017English

Evaluation of Peanut Sublingual Immunotherapy for Peanut Allergy: A Pilot Study

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Epicutaneous Immunotherapy (EPIT) for Peanut Allergy in Young Children

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy